LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Corrigendum: A standardized extract of

    Tena-Garitaonaindia, Mireia / Ceacero-Heras, Diego / Montoro, María Del Mar Maldonado / de Medina, Fermín Sánchez / Martínez-Augustin, Olga / Daddaoua, Abdelali

    Frontiers in microbiology

    2023  Volume 14, Page(s) 1183760

    Abstract: This corrects the article DOI: 10.3389/fmicb.2022.814448.]. ...

    Abstract [This corrects the article DOI: 10.3389/fmicb.2022.814448.].
    Language English
    Publishing date 2023-03-28
    Publishing country Switzerland
    Document type Published Erratum
    ZDB-ID 2587354-4
    ISSN 1664-302X
    ISSN 1664-302X
    DOI 10.3389/fmicb.2023.1183760
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: A Standardized Extract of

    Tena-Garitaonaindia, Mireia / Ceacero-Heras, Diego / Montoro, María Del Mar Maldonado / de Medina, Fermín Sánchez / Martínez-Augustin, Olga / Daddaoua, Abdelali

    Frontiers in microbiology

    2022  Volume 13, Page(s) 814448

    Abstract: The priority pathogen list of the World Health Organization ... ...

    Abstract The priority pathogen list of the World Health Organization classified
    Language English
    Publishing date 2022-03-16
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2587354-4
    ISSN 1664-302X
    ISSN 1664-302X
    DOI 10.3389/fmicb.2022.814448
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Impact of a risk-sharing agreement in rheumatoid arthritis in Spain.

    García-Collado, Carlos Gustavo / Martínez-de-la-Plata, Juan Enrique / Montoro, María Del Mar Maldonado / Morales, Alberto Jiménez / Hernández, Miguel Ángel Calleja / Martínez, Fernando Martínez

    Health policy (Amsterdam, Netherlands)

    2020  Volume 125, Issue 3, Page(s) 335–340

    Abstract: Context and objective: Risk-sharing agreements(RSA) allow decision-makers to manage the uncertainty associated with effectiveness and costs of treatments. Our objective was to estimate the economic impact of RSA implementation on treatment of patients ... ...

    Abstract Context and objective: Risk-sharing agreements(RSA) allow decision-makers to manage the uncertainty associated with effectiveness and costs of treatments. Our objective was to estimate the economic impact of RSA implementation on treatment of patients diagnosed with rheumatoid arthritis(RA) with certolizumab pegol(CZP) and assess the potential impact of alternative RSA.
    Methods: Under original RSA, treatment with CZP was reimbursed when the response was optimal (DAS28 score <3.2) or satisfactory (DAS28 score ≥3.2 and reduction from baseline ≥1.2) at 12 weeks. Alternative RSA would additionally include a 50 % reimbursement for moderate responders(DAS28 score >3.2 and ≤5.1, and reduction from baseline between 0.6 and 1.2). We estimated average savings per patient for hospital's pharmacy service(HPS) at 12 weeks, taking into account the pharmacological cost of CZP. Uncertainty associated with effectiveness of CZP was assessed through 1000 Monte Carlo simulations.
    Results: After 12 weeks of treatment, 57.8 % (n = 52) and 22.2 %(n = 20) of patients had optimal and satisfactory responses, respectively, and average disease activity improved by 1.77 points. Average savings for HPS amounted to 876.9€ and 706.4€ per patient under original and alternative RSA, respectively. Savings in simulated cohort reached 846.2€ and 681.8€ per patient, respectively, leading to estimated net savings for HPS of 846,209€ and 681,790€, respectively.
    Conclusions: RSA implementation on patients with RA treated with CZP has generated savings and improved efficiency within HPS.
    MeSH term(s) Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Certolizumab Pegol/therapeutic use ; Drug Therapy, Combination ; Humans ; Spain ; Treatment Outcome
    Chemical Substances Antirheumatic Agents ; Certolizumab Pegol (UMD07X179E)
    Language English
    Publishing date 2020-11-16
    Publishing country Ireland
    Document type Journal Article
    ZDB-ID 605805-x
    ISSN 1872-6054 ; 0168-8510
    ISSN (online) 1872-6054
    ISSN 0168-8510
    DOI 10.1016/j.healthpol.2020.11.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2250: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top